Business Context and Reporting Period
Company: ANAPTYSBIO, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: May 29, 2026
Event: Regulation FD Disclosure regarding the separation and spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate transaction rather than periodic financial performance.
Material Changes
- Spin-off Transaction: The Company has completed the separation and spin-off of First Tracks Biotherapeutics, Inc.
- Dividend Distribution: Stockholders received a dividend consisting of First Tracks common stock.
- Tax Documentation: The Company filed Form 8937 with the IRS to provide details on the dividend and guidance on tax basis changes.
Guidance, Outlook, and Risks
- Tax Implications: The filing explicitly states that stockholders should consult their own tax advisors regarding potential tax consequences under federal, state, local, and non-U.S. tax laws.
- Disclaimer: The information provided is for informational purposes only and does not constitute legal or tax advice.
- Liability: The information furnished in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific number of First Tracks shares received per AnaptysBio share held.
- Review the filed Form 8937 on the Company's website or IRS records for detailed tax basis calculations.
- Confirm the trading symbol and listing status of First Tracks Biotherapeutics, Inc. post-spin-off.
- Consult a tax professional regarding the specific tax treatment of the distribution in your jurisdiction.